Sunovion Adds Parkinson's To CNS Franchise With Cynapsus Buyout
Executive Summary
Sumitomo Dainippon unit pays a 123% premium to acquire Cynapsus and its Phase III Parkinson's drug APL-130277, with at least one analyst speculating it paid a high price in order to avoid a bidding war.
You may also be interested in...
Sunovion Must Regroup After Setback With Dasotraline In ADHD
Sunovion must find a new path forward for its dasotraline in attention deficit/hyperactivity disorder (ADHD), following a complete response letter from the US FDA.
Keeping Track Of Good News For AstraZeneca, Pfizer, Promius, And Sunovion
NDA and BLA submission news from our US FDA Performance Tracker.
Acorda Investor Scopia Seeks Big Return From Sale Of The Company
Citing recent deals, hedge fund Scopia encouraged Acorda's board on Aug. 7 to pursue a sale, but the company believes its new strategy focused on Parkinson's disease is best for shareholders.